Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pet Anthelmintic Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pet Anthelmintic Drugs market research.
Key companies engaged in the Pet Anthelmintic Drugs industry include Elanco, Boehringer Ingelheim, Ceva Sante Animale, Chanelle Group, Dechra, Durvet, First Priority, Jeffers and Manna Pro Products, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Pet Anthelmintic Drugs were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Pet Anthelmintic Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pet Anthelmintic Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company (Partial List):
Segment by Type
Segment by Application
Consumption by Region
The Pet Anthelmintic Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pet Anthelmintic Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 External
1.2.3 Internal
1.2.4 Composite
1.2.5 Injection
1.3 Market by Application
1.3.1 Global Pet Anthelmintic Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Dog
1.3.3 Cat
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pet Anthelmintic Drugs Market Perspective (2018-2029)
2.2 Pet Anthelmintic Drugs Growth Trends by Region
2.2.1 Global Pet Anthelmintic Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Pet Anthelmintic Drugs Historic Market Size by Region (2018-2023)
2.2.3 Pet Anthelmintic Drugs Forecasted Market Size by Region (2024-2029)
2.3 Pet Anthelmintic Drugs Market Dynamics
2.3.1 Pet Anthelmintic Drugs Industry Trends
2.3.2 Pet Anthelmintic Drugs Market Drivers
2.3.3 Pet Anthelmintic Drugs Market Challenges
2.3.4 Pet Anthelmintic Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pet Anthelmintic Drugs Players by Revenue
3.1.1 Global Top Pet Anthelmintic Drugs Players by Revenue (2018-2023)
3.1.2 Global Pet Anthelmintic Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Pet Anthelmintic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pet Anthelmintic Drugs Revenue
3.4 Global Pet Anthelmintic Drugs Market Concentration Ratio
3.4.1 Global Pet Anthelmintic Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pet Anthelmintic Drugs Revenue in 2022
3.5 Pet Anthelmintic Drugs Key Players Head office and Area Served
3.6 Key Players Pet Anthelmintic Drugs Product Solution and Service
3.7 Date of Enter into Pet Anthelmintic Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pet Anthelmintic Drugs Breakdown Data by Type
4.1 Global Pet Anthelmintic Drugs Historic Market Size by Type (2018-2023)
4.2 Global Pet Anthelmintic Drugs Forecasted Market Size by Type (2024-2029)
5 Pet Anthelmintic Drugs Breakdown Data by Application
5.1 Global Pet Anthelmintic Drugs Historic Market Size by Application (2018-2023)
5.2 Global Pet Anthelmintic Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Pet Anthelmintic Drugs Market Size (2018-2029)
6.2 North America Pet Anthelmintic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Pet Anthelmintic Drugs Market Size by Country (2018-2023)
6.4 North America Pet Anthelmintic Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pet Anthelmintic Drugs Market Size (2018-2029)
7.2 Europe Pet Anthelmintic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Pet Anthelmintic Drugs Market Size by Country (2018-2023)
7.4 Europe Pet Anthelmintic Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pet Anthelmintic Drugs Market Size (2018-2029)
8.2 Asia-Pacific Pet Anthelmintic Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Pet Anthelmintic Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Pet Anthelmintic Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pet Anthelmintic Drugs Market Size (2018-2029)
9.2 Latin America Pet Anthelmintic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Pet Anthelmintic Drugs Market Size by Country (2018-2023)
9.4 Latin America Pet Anthelmintic Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pet Anthelmintic Drugs Market Size (2018-2029)
10.2 Middle East & Africa Pet Anthelmintic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Pet Anthelmintic Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Pet Anthelmintic Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Elanco
11.1.1 Elanco Company Detail
11.1.2 Elanco Business Overview
11.1.3 Elanco Pet Anthelmintic Drugs Introduction
11.1.4 Elanco Revenue in Pet Anthelmintic Drugs Business (2018-2023)
11.1.5 Elanco Recent Development
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Company Detail
11.2.2 Boehringer Ingelheim Business Overview
11.2.3 Boehringer Ingelheim Pet Anthelmintic Drugs Introduction
11.2.4 Boehringer Ingelheim Revenue in Pet Anthelmintic Drugs Business (2018-2023)
11.2.5 Boehringer Ingelheim Recent Development
11.3 Ceva Sante Animale
11.3.1 Ceva Sante Animale Company Detail
11.3.2 Ceva Sante Animale Business Overview
11.3.3 Ceva Sante Animale Pet Anthelmintic Drugs Introduction
11.3.4 Ceva Sante Animale Revenue in Pet Anthelmintic Drugs Business (2018-2023)
11.3.5 Ceva Sante Animale Recent Development
11.4 Chanelle Group
11.4.1 Chanelle Group Company Detail
11.4.2 Chanelle Group Business Overview
11.4.3 Chanelle Group Pet Anthelmintic Drugs Introduction
11.4.4 Chanelle Group Revenue in Pet Anthelmintic Drugs Business (2018-2023)
11.4.5 Chanelle Group Recent Development
11.5 Dechra
11.5.1 Dechra Company Detail
11.5.2 Dechra Business Overview
11.5.3 Dechra Pet Anthelmintic Drugs Introduction
11.5.4 Dechra Revenue in Pet Anthelmintic Drugs Business (2018-2023)
11.5.5 Dechra Recent Development
11.6 Durvet
11.6.1 Durvet Company Detail
11.6.2 Durvet Business Overview
11.6.3 Durvet Pet Anthelmintic Drugs Introduction
11.6.4 Durvet Revenue in Pet Anthelmintic Drugs Business (2018-2023)
11.6.5 Durvet Recent Development
11.7 First Priority
11.7.1 First Priority Company Detail
11.7.2 First Priority Business Overview
11.7.3 First Priority Pet Anthelmintic Drugs Introduction
11.7.4 First Priority Revenue in Pet Anthelmintic Drugs Business (2018-2023)
11.7.5 First Priority Recent Development
11.8 Jeffers
11.8.1 Jeffers Company Detail
11.8.2 Jeffers Business Overview
11.8.3 Jeffers Pet Anthelmintic Drugs Introduction
11.8.4 Jeffers Revenue in Pet Anthelmintic Drugs Business (2018-2023)
11.8.5 Jeffers Recent Development
11.9 Manna Pro Products
11.9.1 Manna Pro Products Company Detail
11.9.2 Manna Pro Products Business Overview
11.9.3 Manna Pro Products Pet Anthelmintic Drugs Introduction
11.9.4 Manna Pro Products Revenue in Pet Anthelmintic Drugs Business (2018-2023)
11.9.5 Manna Pro Products Recent Development
11.10 Merck Animal Health
11.10.1 Merck Animal Health Company Detail
11.10.2 Merck Animal Health Business Overview
11.10.3 Merck Animal Health Pet Anthelmintic Drugs Introduction
11.10.4 Merck Animal Health Revenue in Pet Anthelmintic Drugs Business (2018-2023)
11.10.5 Merck Animal Health Recent Development
11.11 Ourofino
11.11.1 Ourofino Company Detail
11.11.2 Ourofino Business Overview
11.11.3 Ourofino Pet Anthelmintic Drugs Introduction
11.11.4 Ourofino Revenue in Pet Anthelmintic Drugs Business (2018-2023)
11.11.5 Ourofino Recent Development
11.12 TTK Healthcare
11.12.1 TTK Healthcare Company Detail
11.12.2 TTK Healthcare Business Overview
11.12.3 TTK Healthcare Pet Anthelmintic Drugs Introduction
11.12.4 TTK Healthcare Revenue in Pet Anthelmintic Drugs Business (2018-2023)
11.12.5 TTK Healthcare Recent Development
11.13 Vetoquinol
11.13.1 Vetoquinol Company Detail
11.13.2 Vetoquinol Business Overview
11.13.3 Vetoquinol Pet Anthelmintic Drugs Introduction
11.13.4 Vetoquinol Revenue in Pet Anthelmintic Drugs Business (2018-2023)
11.13.5 Vetoquinol Recent Development
11.14 Virbac
11.14.1 Virbac Company Detail
11.14.2 Virbac Business Overview
11.14.3 Virbac Pet Anthelmintic Drugs Introduction
11.14.4 Virbac Revenue in Pet Anthelmintic Drugs Business (2018-2023)
11.14.5 Virbac Recent Development
11.15 Zoetis
11.15.1 Zoetis Company Detail
11.15.2 Zoetis Business Overview
11.15.3 Zoetis Pet Anthelmintic Drugs Introduction
11.15.4 Zoetis Revenue in Pet Anthelmintic Drugs Business (2018-2023)
11.15.5 Zoetis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research